For HER2 positive NSCLC patients, enrollment of patients in clinical trials with novel agents targeting HER2 or downstream components of the MEK/ERK and PI3K/AKT/mTOR pathway is another option. This evidence concerns the gene MTOR and non-small cell lung carcinoma.